Skip to main content
Collection

Meningococcal B (MenB) vaccination for infants programme

Documents relating to the meningococcal B (MenB) vaccination (Bexsero®) programme for infants.

Updates to this page

From:
UK Health Security Agency
Published:
30 June 2015
Last updated:
20 March 2026
Show all updates

  1. Added: Meningococcal disease outbreak resources.

  2. The document collection has been updated to reflect the changes to the childhood immunisation schedule from 01 July 2025, including changes to the schedule of MenB vaccines given.

  3. Added link to the Meningococcal B vaccination for infants aged from 8 weeks training slideset.

  4. Added information on immunisation patient group direction (PGD) templates.

  5. Addition of link to MenB vaccine coverage estimates

  6. Additional information added regarding MenB and Paracetamol

  7. Added training guide for healthcare professionals.

  8. Added 2 guides for parents on meningitis and septicaemia caused by meningococcal group B disease.

  9. First published.

Meningococcal disease is caused by invasive infection with the bacterium Neisseria meningitidis, also known as the meningococcus.

There are 12 identified capsular groups of which groups B, C, W and Y were historically the most common in the UK.

The MenB vaccine (Bexsero®) protects against meningococcal disease capsular group B. The vaccine was added to the childhood immunisation programme as part of the routine schedule in England from 1 September 2015. Changes to the schedule for MenB vaccination have been made from 01 July 2025.

Data and reports on the uptake of the MenB vaccine for England are published by UK Health Security Agency.

Immunisation patient group direction (PGD) templates are available for authorisation and adoption to provide NHS routine immunisation services.

Guidance for healthcare professionals

Posters and leaflets

Outbreak resources

Programme documents

Contents